Kanamab (Ilaris) is a selective IL-1 β inhibitor primarily used for the treatment of periodic fever syndrome and autoimmune inflammatory diseases. It is administered via intravenous infusion and requires strict adherence to dose escalation protocols and regular monitoring requirements.

1. Indications and mechanisms of action

(1) Indications: Suitable for Cold Pyrroline Associated Periodic Syndrome (CAPS), Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), etc

(2) Mechanism: By binding IL-1 β with high affinity and blocking its interaction with receptors, the inflammatory cascade reaction is inhibited

2 Usage and dosage specifications

(1) Adult dose: initial 150mg subcutaneous injection, once every 8 weeks; Some patients may need to adjust to 300mg every 8 weeks

(2) Child dose: Calculated at 2mg/kg for patients aged 4-17 years, with a maximum dose not exceeding 150mg, once every 8 weeks

(3) Administration method: It needs to be operated by medical professionals, and the injection site should be selected in the abdomen or thigh

3 Principles of Dose Adjustment

(1) Insufficient therapeutic effect: If symptoms are not well controlled, it may be considered to increase to 300mg every 8 weeks, but the risk of infection needs to be evaluated

(2) Adverse reactions: In the event of severe infection, medication should be suspended and the medication regimen should be re evaluated after recovery

4 Special Medication Precautions

(1) Infection monitoring: tuberculosis screening is required before medication, and infection signs should be closely observed during treatment

(2) Vaccination: All immunizations should be completed before the start of treatment to avoid the use of live vaccines

(3) Liver and kidney function: mild to moderate abnormalities do not require dose adjustment, patients with end-stage renal disease should use with caution

5 Adverse Reaction Management

(1) Common reactions: Injection site reaction (15%), upper respiratory tract infection (10%), headache (7%)

(2) Serious risks: Beware of serious infections (including tuberculosis recurrence), allergic reactions, and neutropenia